Masoli Matthew, Williams Mathew, Weatherall Mark, Beasley Richard
Medical Research Institute of New Zealand, P.O. Box 10055, Wellington 6001, New Zealand.
Respir Med. 2006 Jan;100(1):20-5. doi: 10.1016/j.rmed.2005.04.012. Epub 2005 Jun 3.
The duration of bronchodilator action of the long-acting beta-agonist formoterol when administered in the evening has not been investigated. In this study we have investigated whether a single evening dose of formoterol, administered from the combination budesonide/formoterol (BUD/F) Turbuhaler significantly attenuates the circadian rhythm in airway tone over 24 h.
Twenty subjects with mild to moderate asthma (mean FEV1 84% predicted) participated in a double-blind, placebo-controlled, cross-over study. Subjects inhaled, in random order, placebo or BUD/F (2x100/6 microg) administered in the evening (2000 h) on two separate occasions. Lung function measurements including FEV1, specific airways conductance (sGaw) and maximum expiratory flow at 25-75% of vital capacity (MEF(25-75%)) were assessed at baseline, at 1 h and subsequently every 4 h post-dose for 24 h.
Compared with placebo, BUD/F significantly improved the three measures of airways function throughout the 24 h period, with a difference in FEV1 at 24 h of 0.20L (0.04-0.35L). BUD/F attenuated the biphasic pattern of the circadian rhythm in airway tone.
The single evening administration of formoterol from the combination BUD/F inhaler resulted in a duration of bronchodilation of at least 24 h.
长效β受体激动剂福莫特罗在晚间给药时支气管扩张作用的持续时间尚未得到研究。在本研究中，我们调查了从布地奈德/福莫特罗（BUD/F）都保吸入器单次晚间给药的福莫特罗是否能在24小时内显著减弱气道张力的昼夜节律。
20名轻度至中度哮喘患者（平均FEV1为预测值的84%）参与了一项双盲、安慰剂对照、交叉研究。受试者在两个不同的场合随机顺序吸入晚间（20:00）给予的安慰剂或BUD/F（2×100/6微克）。在基线、给药后1小时以及随后24小时内每4小时评估一次肺功能指标，包括FEV1、比气道传导率（sGaw）和肺活量25%-75%时的最大呼气流量（MEF(25-75%)）。
与安慰剂相比，BUD/F在整个24小时期间显著改善了三项气道功能指标，24小时时FEV1的差异为0.20L（0.04 - 0.35L）。BUD/F减弱了气道张力昼夜节律的双相模式。
从BUD/F吸入器单次晚间给予福莫特罗导致支气管扩张持续时间至少为24小时。
